BRAF and melanoma: These data indicates that resistance to anoikis driven by elevated integrin receptor expression and FAK signaling is functionally separable from the collateral sensitivity to HMGCR inhibitors seen in chronic treated BRAF inhibitor resistant melanoma cells with silenced PGC1α expression.